Effects of L-carnitine on treatment outcomes of COVID-19 patients hospitalized in intensive care units:A double-blind randomized clinical trial  

作　　者：Hesameddin Modir Behnam Mahmoudieh Seyed Yousef Shahtaheri Fariba Farokhi 

机构地区：[1]Department of Anesthesiology and Critical Care,Arak University of Medical Sciences,Arak,Iran [2]Clinical Research Development,Valiasr Hospital,Arak University of Medical Sciences,Arak,Iran

出　　处：《Journal of Acute Disease》2024年第3期100-105,共6页急性病杂志（英文版）

摘　　要：Objective:To assess the effects of L-carnitine on the outcomes of patients with moderate to severe coronavirus disease 2019(COVID-19)in intensive care unit(ICU).Methods:This double-blind clinical trial was carried out in 2022-2023.64 Patients with COVID-19 were selected from Amiralmomenin and Khansari hospitals in Arak,Iran.They were randomly assigned to the control and the L-carnitine treatment group via block randomization.Venous blood gases,disease severity,and levels of D-dimer,lactate dehydrogenase,ferritin,and C-reactive protein were daily assessed during the seven days of the intervention,and the length of ICU stay,the need for endotracheal intubation,and mortality rate were documented.Results:There were significant differences in length of ICU stay,the need for endotracheal intubation,and levels of D-dimer,lactate dehydrogenase,ferritin,APACHE栻score,and C-reactive protein between the two groups(P<0.05).However,the groups did not significantly differ in mortality rate and venous blood gas indexes(P>0.05).Conclusions:L-carnitine can improve outcomes of patients with COVID-19.Therefore,it can be used as an adjuvant therapy for these patients.

关 键 词：L-CARNITINE COVID-19 ICU Critically ill MORTALITY Clinical outcome 

分 类 号：R563.1[医药卫生—呼吸系统]